Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Healthtrust
AstraZeneca
US Department of Justice
Cerilliant
Mallinckrodt
Harvard Business School
Citi

Generated: June 21, 2018

DrugPatentWatch Database Preview

HYZAAR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for HYZAAR
Pharmacology for HYZAAR
Synonyms for HYZAAR
(1-((2-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YL)METHANOL
(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol
(1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol
(1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
(2-BUTYL-4-CHLORO-1-[[2'-(2H-TETRAZOL-5-YL)-4-BIPHENYLYL]METHYL]-1H-IMIDAZOL-5-YL)METHANOL
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
[2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
[2-butyl-5-chloro-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolyl]methanol
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
[3H]-losartan
[3H]losartan
{2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol
114798-26-4
124750-99-8 (mono-potassium salt)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI)
1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol
2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL
2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole
2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole
2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
54244-EP2269989A1
54244-EP2270011A1
54244-EP2272841A1
54244-EP2277879A1
54244-EP2287165A2
54244-EP2287166A2
54244-EP2292620A2
54244-EP2295053A1
54244-EP2295406A1
54244-EP2298772A1
54244-EP2298776A1
54244-EP2298779A1
54244-EP2301923A1
54244-EP2301931A1
54244-EP2301936A1
54244-EP2305219A1
54244-EP2308562A2
54244-EP2308839A1
798L264
A803239
AB0013723
AB01563296_01
AB07507
AC1L1H3Q
AK326126
AKOS015917390
AKOS015994740
allisartan
AN-15301
API0007066
BCP9000861
BCPP000183
BDBM82258
BG0556
BIDD:GT0286
BRD-K76205745-001-02-5
BSPBio_002695
C07072
C22H23ClN6O
CAS_114798-26-4
CAS-114798-26-4
CCG-39095
CHEBI:6541
CL23623
Cozaar
Cozaar (TN)
CS-2116
CTK8E7663
D03AQG
D08146
D0DD0K
DB00678
DR002602
DSSTox_CID_3227
DSSTox_GSID_23227
DSSTox_RID_76933
DTXSID7023227
DuP 753
DUP 89
DuP-753
EC 601-329-8
Epitope ID:140137
F2173-0506
FT-0631074
GP6564
GTPL3941
GTPL590
HE298246
HMS1922J13
HMS2093E22
HSDB 7043
HY-17512
I14-9710
I497
JMS50MPO89
Jsp001094
KBio2_002193
KBio2_004761
KBio2_007329
KBio3_001915
KBioGR_001611
KBioSS_002193
KS-00000GI2
KS-5004
L000351
Lortaan
losartan
Losartan (INN)
Losartan [INN:BAN]
losartan monopotassium
Losartan monopotassium salt
LOSARTAN POTASSIUM
Losartic
Losartic (TN)
LS-78746
MCULE-5204931675
MFCD00865831
MK-954
MK954
MolPort-003-666-553
MolPort-006-167-607
NCGC00095125-01
NCGC00095125-02
NCGC00095125-03
NCGC00095125-05
NSC_3961
NSC-758699
NSC758699
Oprea1_644635
OSCAAR
Pharmakon1600-01504268
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
PubChem9176
Q-201321
RT-013597
SBI-0206766.P001
SC-47229
SCHEMBL60
SPBio_001893
Spectrum_001713
SPECTRUM1504268
Spectrum2_001677
Spectrum3_000998
Spectrum4_001126
Spectrum5_001466
STL419984
Tox21_111435
Tox21_111435_1
UNII-JMS50MPO89
ZINC3873160

US Patents and Regulatory Information for HYZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-001 Apr 28, 1995 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-003 Oct 20, 2005 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-002 Nov 10, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for HYZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-001 Apr 28, 1995 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-003 Oct 20, 2005 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-002 Nov 10, 1998 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-001 Apr 28, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HYZAAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 100 mg/12.5 mL ➤ Subscribe 2006-04-04
➤ Subscribe Tablets 50 mg/12.5 mg and 100 mg/25 mg ➤ Subscribe 2004-05-24

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Merck
Moodys
Colorcon
McKinsey
Fuji
Cipla
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.